https://www.selleckchem.com/pr....oducts/Sodium-butyra
OS rates for the pre-sarcopenia group (n=41) were worse than those for the non-pre-sarcopenia group (n=11 (0.5-, 1-, and 1.5-year OS 72.5%, 27.9%, and 7.0% vs 80.7%, 56.7%, and 46.1%, respectively; P0.001), as was progression-free survival (P=0.025). Time to stopping lenvatinib or disease progression was better in the non-pre-sarcopenia group (0.5-, 1-, and 1.5-year OS 48.0%, 24.5%, and 8.4% vs 20.0%, 10.3%, and 4.2%, respectively; P0.001). Also, the frequency of the adverse event appetite loss (any grade) was greater
Like
Comment
Share
